Larazotide

Larazotide

Larazotide

Larazotide, he waha liilii, ʻOkoʻa ka peptide synthetic a me kahi antagonist koho o zonulin mai nā lāʻau lapaʻau ʻē aʻe no ka mea ʻaʻole hoʻopaʻa kēia pūhui i kekahi mea loaʻa..

Pane wikiwiki

Reliable Larazotide peptide provided by professional manufacturer and factory. Offer wholesale AT-1001 intestinal barrier regulatory peptides for biomedical laboratory and immune disease research projects.

SKU: 198847 Māhele:
Kaʻana like i kāu aloha

Larazotide, he waha liilii, peptide synthetic a me kahi antagonist koho o zonulin He ʻokoʻa ia mai nā lāʻau lapaʻau ʻē aʻe no ka mea ʻaʻole hoʻopaʻa kēia pūhui i kekahi mea loaʻa.

He hana ma kahi adjuvant kuleana (i loaʻa mai ka palapala a me ke kamaʻilio pilikino) ma ka hoʻomaʻamaʻa ʻana i kahi pale ʻōpū dysfunctional i ʻike ʻia ma ka liʻiliʻi ma maʻi celiac.

Kāohi ʻo Larazotide i ka wehe ʻana o ka hui ʻana i ka gluten-mediated a he lāʻau lapaʻau maikaʻi ʻole no ka poʻe maʻi CD ma lalo o  a. GFD.

Ua hōʻike ʻo Larazotide i ka maikaʻi hoʻohiki i ka hoʻomohala ʻana i ka lāʻau lapaʻau ma nā haʻawina Phase IIb, ʻoi loa  no nā hōʻailona mau.

Ma waho aʻe o kāna noi mua i nā maʻi gastrointestinal, Ua hōʻike mua nā haʻawina in vitro i ka hana antiviral o Larazotide ka maʻi varicella-zoster (VZV), e alakaʻi ana i nā noi hou i nā maʻi maʻi.

Ma ke kahua o nā lāʻau lapaʻau, ʻO Larazotide kahi hoʻokō therapeutic peptide waha nui.

Ua hōʻike ʻia ka ʻilihune waha o nā lāʻau peptide maʻamau no ka mea ua hoʻohaʻahaʻa ʻia lākou e nā enzyme GI..

Hāʻawi kēia ʻano hana hou iā ia e hana i nā pahuhopu o ka ʻōpū ma ka ʻāina me ka liʻiliʻi o ka ʻōnaehana systemic absorption, e hōʻemi ana i nā hopena ʻaoʻao systemic.

Kaʻina

H-Gly-Gly-Val-Leu-Val-Gln-Pro-Gly-OH

Helu CAS

258818-34-7

ʻĀpana Molekala

C32H55N9O10

Kaumaha Molekala

725.83

Noiʻi o Larazotide
1.Hoʻomaopopo i ka pahuhopu a me ka hoʻolālā lāʻau

Zonulin, ka protein e hoʻoponopono ai ʻōpū liʻiliʻi (A ME) paracellular permeability i loko o ka reversible a hiki ole Ua ʻike ʻia ke ʻano.

ʻOiai inā ʻo ka ʻano hana o Larazotide ua like ia me kela AT-1001–ʻo ia hoʻi, kahi paʻa o ka zonulin i hoʻopaʻa ʻia i kona mea loaʻa a ma o kēia pale ʻana i ka piʻi ʻana o ka ʻōpū o ka ʻōpū ma o ka attenuation o zonulin mai nā hui paʻa-, ua hoʻāʻo ʻia ʻo ia ka modulator TJ mua i nā kānaka.

Eia naʻe, ma muli o kona kaʻina waika amino ʻokoʻa a me ka hoʻokumu ʻana i ka paʻakai acetate (Larazotide acetate, CAS No 881851-50-9), Larazotide [Ac-KPFSLSQ(Cys)] hōʻike i ke kūpaʻa kiʻekiʻe a me ka bioavailability kūloko i loko o ka ʻōpū.

2.Hoʻololi ʻia o ka hana ʻāʻī o ka ʻōpū

Loaʻa ʻo Larazotide i ka waiwai ʻepekema hohonu ma ke ʻano he ala hou a ikaika hoʻi i ka modulation kikoʻī o ka hana pale ʻōpū..

Hoʻohana nui ʻia kāna hana ma o ka hoʻohālikelike ʻana o zonulin, e hoʻokūkū ana me zonulin no ka hoʻopaʻa ʻana i nā mea loaʻa ma ka ʻili luminal o enterocytes.

ʻO kēia ke alakaʻi ʻana i ka inhibition o intracellular activation o myosin light-chain kinase (MLCK), ʻO ka hoʻonohonoho hou ʻana o ka cytoskeletal a me ka wehe ʻana o nā protein hui paʻa SE-1.

Ma kēia ʻano molekala Larazotide e hoʻopaʻa i ka paʻa o nā hui paʻa a keʻakeʻa i ka unuhi makemake ʻole ʻia. macromolecules e.g., gliadin.

3.Ka mālama ʻana i ka maʻi Celiac

ʻO ka maʻi Celiac (CD) he autoimmune enteropathy, hoʻomaka ʻia e ka ʻike ʻana i ka gluten in genetically predisposed poʻe, a pili e pili ana 1% o ka heluna kanaka o ka honua.

I kēia manawa, ʻO ka mālama ʻana i ka meaʻai gluten-free ka lāʻau lapaʻau i hōʻoia ʻia.

Eia naʻe, paʻakikī ka mālama lōʻihi i ka meaʻai; He paʻakikī paha ka pale ʻana i ka launa ʻana a ke hoʻomau nei nā hōʻailona i nā maʻi he nui.

Ma kona kumu, ʻO ka MOA o Larazotide i loko o ka maʻi celiac ka mea koho koho i ka wehe ʻana o TJ i hoʻokomo ʻia e zonulin.

I ka maʻi celiac, i ka pane ʻana i ka deamidated gliadin peptides, enterocyte CXCR3 Hoʻokomo ʻia ka hoʻokuʻu ʻana o zonulin.

Hoʻopili ka zonulin manuahi me kona loaʻa ma ka papa epithelial, ka hoʻoulu ʻana i nā ala hōʻailona intracellular e alakaʻi i ka myosin light-chain phosphorylation.

ʻO kēia ka hopena i ka relocalization o nā protein hui paʻa (e like me ZO-1, occludin a claudins) a cytoskeleton ka hoʻonohonoho hou ʻana me ka hoʻonui ʻana i ka permeability o ka ʻōpū.

ʻO Larazotide kahi mea hoʻokūkū octapeptide-antagonist, hoʻopaʻapaʻa hoʻokūkū a hoʻohuli ʻia i nā mea loaʻa zonulin ma ka ʻili luminal o nā cell epithelial, e ālai ana i kēia kaʻina hana hōʻailona cascade, a mālama i ka homeostasis pale.

Hoʻokomo ʻia kahi hoʻokolohua lapaʻau Phase IIb 342 nā maʻi me nā hōʻailona hoʻomau i ka hoʻonohonoho ʻana o kahi GFD.

ʻO kahi maʻi o 0.5 Ua hōʻike ʻia ka mg ʻekolu manawa i kēlā me kēia lā i ka maikaʻi a ʻoi aku ka maikaʻi ma mua o ka placebo ma ke ʻano o ka hōʻemi ʻana i nā hōʻailona o ka maʻi gastrointestinal me kahi ʻike palekana a me ka hoʻomanawanui ma mua o ke aʻo hou ʻana..

4.Mea Antiviral

Ma waho aʻe o kāna hoʻohana ʻana i ka ʻōpū ʻāʻā, Ua hōʻailona ʻo Larazotide i ka pono antiviral in vitro e kūʻē iā VZV.

Hoʻonui kēia ʻike i kona hiki ke hoʻōla a hōʻike i nā ʻano hana like ʻole hiki ke hana.

Hōʻike ka hōʻike in vitro ʻo Larazotide ke kāohi i ka hana hou ʻana o VZV OKA a 07-1 ke kaumaha me EC₅₀ o 44.14 μM a 59.06 μM, pakahi.

He haʻahaʻa kēia pae o ka hana no kahi lāʻau antiviral.

Eia naʻe, e like me ka hana o Larazotide i localized me ka 'ano nui puka makani lapaʻau, hoʻohui kēia i ka waiwai nui i ka hoʻomohala ʻana i ke kino.

ʻIke ʻia, ka cytotoxicity o kēia mea hana i loko o nā pūnaewele hoʻokipa (Nā pūnaewele Vero) hōʻike ʻia a CC₅₀ waiwai o 82.5 μM, e hāʻawi ana i kahi lākiō TI o ~1.4-1.9.

Hōʻike kēia i kahi mea palekana haʻahaʻa akā hiki ke ʻae ʻia i nā ʻano antiviral  i kūpono.

COA

HPLC

MS

Kaʻina:

H-Gly-Gly-Val-Leu-Val-Gln-Pro-Gly-OH

CAS:

258818-34-7

M.W:

725.83 g/mol

Home Huli Whatsapp Nā lawelawe Huahana